222 related articles for article (PubMed ID: 32210725)
1. Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging.
Morosi L; Matteo C; Ceruti T; Giordano S; Ponzo M; Frapolli R; Zucchetti M; Davoli E; D'Incalci M; Ubezio P
Int J Biol Sci; 2020; 16(8):1363-1375. PubMed ID: 32210725
[No Abstract] [Full Text] [Related]
2. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
[TBL] [Abstract][Full Text] [Related]
3. Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.
Wu L; Zhong L
J Med Econ; 2019 Feb; 22(2):187-195. PubMed ID: 30522378
[TBL] [Abstract][Full Text] [Related]
4. Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
van Andel L; Rosing H; Zhang Z; Hughes L; Kansra V; Sanghvi M; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
Cancer Chemother Pharmacol; 2018 Jan; 81(1):39-46. PubMed ID: 29043410
[TBL] [Abstract][Full Text] [Related]
5. [New drug approval: Olaparib and niraparib - first line in ovarian cancer].
Delaye M; Rodrigues M
Bull Cancer; 2021 Apr; 108(4):350-351. PubMed ID: 33641880
[No Abstract] [Full Text] [Related]
6. Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines.
Fedier A; Maggi N; Tozzi A; Disler M; Coelho R; Jacob F; Heinzelmann-Schwarz V
Int J Oncol; 2022 Jul; 61(1):. PubMed ID: 35642662
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma.
Nijenhuis CM; Lucas L; Rosing H; Schellens JH; Beijnen JH
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 940():121-5. PubMed ID: 24145016
[TBL] [Abstract][Full Text] [Related]
8. Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells.
Perez JM; Twigg CAI; Guan W; Thomas SN
J Am Soc Mass Spectrom; 2022 Feb; 33(2):242-250. PubMed ID: 34958553
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Guy H; Walder L; Fisher M
Pharmacoeconomics; 2019 Mar; 37(3):391-405. PubMed ID: 30478649
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Characterization of Olaparib in Nanodelivery System and Target Cell Compartments by LC-MS/MS.
Ottria R; Ravelli A; Miceli M; Casati S; Orioli M; Ciuffreda P
Molecules; 2019 Mar; 24(5):. PubMed ID: 30862103
[TBL] [Abstract][Full Text] [Related]
11. Human mass balance study and metabolite profiling of
van Andel L; Zhang Z; Lu S; Kansra V; Agarwal S; Hughes L; Tibben MM; Gebretensae A; Lucas L; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Dec; 35(6):751-765. PubMed ID: 28303528
[TBL] [Abstract][Full Text] [Related]
12. Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
Foote JR; Secord AA; Liang MI; Ehrisman JA; Cohn DE; Jewell E; Havrilesky LJ
Gynecol Oncol; 2019 Mar; 152(3):445-451. PubMed ID: 30876487
[TBL] [Abstract][Full Text] [Related]
13. Indirect comparison of three PARP inhibitors (olaparib, niraparib, and rucaparib) as maintenance treatment in ovarian carcinoma patients responding to platinum therapy.
Mengato D; Cancanelli L; Di Spazio L; Rivano M; Chiumente M; Messori A
Int J Clin Pharmacol Ther; 2022 Aug; 60(8):370-372. PubMed ID: 35652551
[No Abstract] [Full Text] [Related]
14. Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ivy SP; Liu JF; Lee JM; Matulonis UA; Kohn EC
Expert Opin Investig Drugs; 2016; 25(5):597-611. PubMed ID: 26899229
[TBL] [Abstract][Full Text] [Related]
15. Olaparib for the treatment of ovarian cancer.
Bornstein E; Jimeno A
Drugs Today (Barc); 2016 Jan; 52(1):17-28. PubMed ID: 26937492
[TBL] [Abstract][Full Text] [Related]
16. Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practice.
Eakin CM; Ewongwo A; Pendleton L; Monk BJ; Chase DM
Gynecol Oncol; 2020 Oct; 159(1):112-117. PubMed ID: 32811682
[TBL] [Abstract][Full Text] [Related]
17. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
[TBL] [Abstract][Full Text] [Related]
18. Niraparib Shows Superior Tissue Distribution and Efficacy in a Prostate Cancer Bone Metastasis Model Compared with Other PARP Inhibitors.
Snyder LA; Damle R; Patel S; Bohrer J; Fiorella A; Driscoll J; Hawkins R; Stratton CF; Manning CD; Tatikola K; Tryputsen V; Packman K; Mamidi RNVS
Mol Cancer Ther; 2022 Jul; 21(7):1115-1124. PubMed ID: 35499386
[TBL] [Abstract][Full Text] [Related]
19. Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Li H; Tu J; Zhao Z; Chen L; Qu Y; Li H; Yao H; Wang X; Lee DF; Shen J; Wen L; Huang G; Xie X
Theranostics; 2020; 10(21):9477-9494. PubMed ID: 32863940
[No Abstract] [Full Text] [Related]
20. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
